Chapter 3
Potential for Increased Investment Activity in 2025
U.S. Life Sciences Outlook 2025
2 Minute Read
2 Minute Read
Sales transactions of life sciences lab/R&D properties hit their lowest level in over a decade in 2024, largely due to high interest rates and weak supply-and-demand fundamentals.
CBRE Research projects marginally higher investment sales in 2025 for all commercial real estate sectors based on improved macroeconomic trends, lower interest rates and greater demand. Life sciences investment activity may see a slight uptick, although the sector’s surge in new supply in H1 2025 will be a headwind.
Figure 28: Annual Investment Volume of R&D Properties
While conventional office properties have seen cap rates jump to levels not seen in over a decade, cap rates for life sciences properties appeared to stabilize in 2024 and remained below levels a decade ago.
CBRE expects the 10-year Treasury yield to remain above 4% in 2025, suggesting that any potential decline in life sciences cap rates will be marginal.
Figure 29: Average Cap Rates for Office and R&D Properties
Related Insights
-
Press Release
Czech investment market heading towards EUR 3bn. CBRE advised on the largest deals, most recently the sales of Riverside Karlín and OC Stromovka
October 26, 2026
The Czech commercial real estate market has maintained high liquidity throughout 2026, ranking among the most active markets not only within the CEE region but across Europe as a whole. After three quarters, the total investment volume reached EUR 2 billion, with domestic capital accounting for more than 65% of this figure. According to CBRE, the global leader in commercial real estate services, this amount will approach the EUR 3 billion mark by December. The final result will be significantly driven by the recent sales of the Riverside Karlín office complex and the Stromovka Shopping Center, both of which rank among the most prominent transactions of the year.